About Three Arch Partners
Three Arch Partners is a venture capital firm founded in 1993. It is primarily based out of San Mateo, United States. As of Jun 2017, Three Arch Partners has invested in 74 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series G round of NeuroStar Overall, Three Arch Partners portfolio has seen 5 IPOs and 44 acquisitions including key companies like NeuroStar, MEI Pharma and U.S.HealthWorks. A lot of funds co-invest with Three Arch Partners, with names like New Leaf Venture Partners sharing a substantial percentage of its portfolio. Three Arch Partners has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 8 more
Portfolio Acquisitions
Three Arch Partners' List of Top Investments
Three Arch Partners has a portfolio of 74 companies. Their most notable investments are in Satiety and radiantmedical.com.Their portfolio spans across United States, Belgium, Singapore and 1 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 4 other sectors, across stages such as Series B, Series A and 8 more. Here is the list of top investments by Three Arch Partners:1. NeuroStar
Provider of a non-drug non-invasive therapeutic devices for neurorehabilitation. It focuses on the therapeutic applications of the MRI-strength pulsed magnetic field for treating disorders of the central nervous system. The TMS Therapy is an FDA cleared device used for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Key facts about NeuroStar
- Founded Year: 2003
- Location: Malvern (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $119M
- Employee Count: 211 as on May 31, 2026
- Investors: Quaker Partners Management, Industry Ventures and 14 Others
- Latest Funding Round: Conventional Debt, Mar 02, 2020, $*****
- Highlight: Public
2. Neuronetics
Transforming neurohealth with innovative, non-drug TMS therapy for mental health. The company is dedicated to improving the lives of individuals suffering from psychiatric disorders by offering patient-centric medical devices. They specialize in transcranial magnetic stimulation (TMS) treatment, providing a non-drug, non-invasive alternative for those with depression and OCD. Committed to practice success, they offer ongoing support and strive to expand their capabilities to cover additional indications. Their approach focuses on compassion, innovation, and growth, aiming to provide a safe, effective, and durable treatment option. They are committed to compliance and ethical practices, ensuring the highest quality of care for both patients and healthcare providers.
Key facts about Neuronetics
- Founded Year: 2001
- Location: Malvern (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Series G
- Total Funding till date: $178M
- Employee Count: 216 as on Mar 31, 2026
- Investors: Western Technology Investment, Quaker Partners Management and 16 Others
- Latest Funding Round: Series G, Jun 06, 2017, $*****
3. MEI Pharma
Developer of targeted therapies for the treatment of cancer. The portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) for the treatment of Myelodysplastic Syndrome, Myelofibrosis. The pipeline also includes ME-401, a highly selective oral PI3K delta inhibitor that is being developed for the treatment of B-Cell Malignancies such as recurrent CLL or follicular NHL, and ME-344, a novel mitochondrial inhibitor for the treatment of HER2-negative breast cancer.
Key facts about MEI Pharma
- Founded Year: 2000
- Location: San Diego (United States)
- Annual Revenue: $50M - $100M as on Jun 30, 2024
- Stage: Public
- Employee Count: 111 as on May 31, 2026
- Investors: CAM Capital, Perceptive Advisors and 21 Others
- Latest Funding Round: Post IPO, Jul 18, 2025, $*****
- Highlight: Public
Digital workplace healthcare management tool. The platform developed by the company assists with telehealth communication and service for employees.
Key facts about U.S.HealthWorks
- Founded Year: 1995
- Location: Tukwila (United States)
- Stage: Acquired
- Total Funding till date: $85.5M
- Employee Count: 554 as on May 31, 2026
- Investors: Morgan Stanley, HealthInvest Equity Partners and 9 Others
- Latest Funding Round: Conventional Debt, Jan 22, 2011, $*****
- Highlight: Acquired
5. Epocrates
Clinical decision support tool providing continually updated medical content for clinicians. It offers essential, researched, and updated clinical content to healthcare professionals. The platform delivers in-depth clinical information, enabling providers to prescribe safely and efficiently at the point of care. It is a software solution designed to be a reliable resource for medical professionals, offering features that support informed decision-making. The company focuses on providing accurate and condensed data, ensuring clinicians have access to trusted information. It is a B2B tech company offering a valuable tool for modern medical practice, enhancing patient care through accessible and reliable medical knowledge.
Key facts about Epocrates
- Founded Year: 1998
- Location: San Mateo (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $35M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Saints Capital, Millennium Technology Value Partners and 8 Others
- Latest Funding Round: Series C, Aug 19, 2002, $*****
- Highlight: Acquired
Three Arch Partners' Year-on-Year Investment Trends
Three Arch Partners has invested in 74 companies over the last 29 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in NeuroStar and most recent follow-on round was in Neuronetics.Three Arch Partners' Investments by Stage
Three Arch Partners has made 17 investments in Series B stage with an average round size of $28M, 11 investments in Series A stage with an average round size of $11.9M and 10 investments in Series C stage with an average round size of $22.4M.Stage of entry | No. of Investments |
|---|---|
Series B | 17 |
Series A | 11 |
Series C | 10 |
Series D | 6 |
Post IPO | 3 |
Others | 7 |
Note: We have considered here, only first round of investments
Three Arch Partners' Investments by Sector
Three Arch Partners has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, Healthcare and High Tech. Notably, it has invested in 53 Enterprise (B2B) companies, 52 Tech companies, 26 Software companies and at least 20 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 41 |
Enterprise Applications | 9 |
HealthTech | 8 |
Healthcare | 6 |
High Tech | 5 |
Others | 7 |
Note: We have considered here, only first round of investments
Three Arch Partners' Investments by Geography
Three Arch Partners has made most investments in United States (51), followed by Belgium where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 51 |
Belgium | 1 |
Singapore | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Three Arch Partners' recent investments
Three Arch Partners has not made any investment in 2026 so far.Here are the most recent investments by Three Arch Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 13, 2017 | United States | Series G | 5117 | [+10] | |
Jun 06, 2017 | United States | Series G | 2280 | [+10] | |
Nov 20, 2013 | United States | Post IPO | 7682 | [+6] | |
Mar 14, 2013 | United States | Series A | 6593 | ||
Mar 07, 2013 | United States | Series C | 7902 |
IPOs and Publicly Listed companies in Three Arch Partners' Portfolio
5 of Three Arch Partners' portfolio companies have become public. NeuroStar got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2018 at marketcap of $285M and Talphera got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $96.9M.Here are Three Arch Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 28, 2018 | Jun 13, 2017 | Series G | 7693 | |
Feb 11, 2011 | - | - | 2404 | |
Dec 19, 2003 | Nov 05, 2012 | Post IPO | 9228 | |
- | - | - | 8465 | |
- | Oct 16, 2007 | Series C | 1687 |
Acquired companies in Three Arch Partners' Portfolio
44 companies from Three Arch Partners' portfolio have been acquired. The most recent acquisition was Nevro in Feb 2025 by Globus Medical for $*****.Here are Three Arch Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 06, 2025 | Dec 04, 2006 | Seed | 9247 | |
Jan 19, 2023 | Nov 30, 2006 | Series B | 9293 | |
Jan 17, 2023 | Jan 2007 | Series D | 4828 | |
Apr 12, 2021 | Oct 17, 2008 | Series B | 2403 | |
Dec 16, 2020 | Jan 07, 2008 | Series B | 6786 |
Team profile of Three Arch Partners
Three Arch Partners has a team of 2 members including 2 Partners located in United States. Three Arch Partners' team does not sit on the board of any company as of now.Co-investors of Three Arch Partners
Over the past 29 years, 246 investors have co-invested in Three Arch Partners's portfolio companies. This includes funds and angels.
- Invested before Three Arch Partners: Boston Scientific, Accuitive Medical Ventures and 31 others have invested in rounds before Three Arch Partners. There are 2 companies where Boston Scientific has invested before Three Arch Partners and 1 company where Accuitive Medical Ventures has invested before Three Arch Partners.
- Top Co-investors of Three Arch Partners: 117 investors entered a company along with Three Arch Partners. These include investors like New Leaf Venture Partners (7 companies).
- Invested after Three Arch Partners: A total of 96 investors have invested in Three Arch Partners's portfolio after their investments. Top Investors include Medtronic (4 companies), New Enterprise Associates (2 companies) and CRG (2 companies).
Recent News related to Three Arch Partners
•
Medical device company Neuronetics pulls in $15 mlnPE Hub•Jun 06, 2017•NeuroStar, Neuronetics, Ascension Ventures, Accuitive Medical Ventures and 10 others
•
Ocera raises $28M for PhIIb liver disease study | FierceBiotechFierce Biotech•Nov 06, 2013•Ocera Therapeutics, Venrock, Great Point Partners, QVT Family Office and 5 others
•
Nevro Raises $48M for Medical Devices - PE HubPE Hub•Mar 07, 2013•Nevro, New Enterprise Associates, , Accuitive Medical Ventures and 5 others
•
•
Nevro Raises $58M For Chronic Pain TreatmentMassinvestor•Jul 20, 2011•Nevro, JJDC, Aberdare Ventures, Accuitive Medical Ventures and 3 others
•
•
VisionCare Ophthalmic Technologies Closes $31M Series E Financing |FinSMEsFinSMEs•Jan 10, 2011•Samsara Vision, Giza Venture Capital, Pitango, Three Arch Partners and 2 others
•
NeuroVista Raises $21.5M More Through VC Round and Investment From CyberonicsXconomy•Aug 25, 2010•NeuroVista, Advanced Technology Ventures, Delphi Ventures, Three Arch Partners and 5 others
•
Life science startup Ingenuity Systems brings in $15.4M | VentureBeatVentureBeat•Jul 02, 2010•Ingenuity Systems, Accel, Morgan Stanley, Three Arch Partners
•
